After FLT3 mutations, IDH1 and IDH2 mutations represent the next two most common types of gene mutations in AML for which there are approved, targeted therapies, and there is evidence to support their use for the treatment of post-allo-HCT relapse. Here, FLT3 is linked to acute myeloid leukemia.